Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicet BioLTS:0HX7 -3.28%23 Days Payable is 247.93 as of Jun. 2026. GuruFocus rates LTS:0HX7 with a GF Score™ of 23/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 706 Biotechnology companies, Adicet Bio ranks worse than 141642.92% on this metric.
Adicet Bio's average Accounts Payable for the
three
months ended in Jun. 2026 was $3.26 Mil. Adicet Bio's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $1.20 Mil.
Hence, Adicet Bio's Days Payable for the
three
months ended in Jun. 2026 was 247.93.
The historical rank and industry rank for Adicet Bio's Days Payable or its related term are showing as below:
LTS:0HX7's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 111.165 * Ranked among companies with meaningful Days Payable only.
Adicet Bio's Days Payable
increased
from Jun. 2025 (219.43) to Jun. 2026 (247.93).
It may suggest that Adicet Biodelayed paying its suppliers.
The historical data trend for Adicet Bio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HX7 vs OKYO, GOSS, ACRV: Days Payable Comparison
For the Biotechnology subindustry, Adicet Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's Days Payable distribution charts can be found below:
* The bar in red indicates where Adicet Bio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Adicet Bio's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (LTS:0HX7) has a Days Payable of 247.93 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Adicet Bio and its competitors. According to the industry distribution chart, Adicet Bio ranks #999999 out of 706 companies in the Biotechnology industry.
Is Adicet Bio's Days Payable too high?
Adicet Bio's current Days Payable is 247.93. The Biotechnology industry median Days Payable is 111.17. Adicet Bio's value of 247.93 is 123% above this industry median. Based on the distribution chart, Adicet Bio ranks #999999 out of 706 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adicet Bio has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Days Payable compare to OKYO and GOSS?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #999999 out of 706 companies for Days Payable. This places Adicet Bio in the lower half of its industry. The industry median Days Payable is 111.17. Adicet Bio's value of 247.93 is 123% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.17, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adicet Bio's current Days Payable of 247.93 is 123% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Adicet Bio and its competitors. For the Biotechnology industry, the median Days Payable is 111.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adicet Bio's current Days Payable is 247.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Based on GuruFocus' analysis, Adicet Bio (LTS:0HX7) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $8.82 — trading 1860.3% above its estimated fair value. The current Days Payable is 247.93 and 123% above the Biotechnology industry median of 111.17. Adicet Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Adicet Bio (LTS:0HX7), the current Days Payable is 247.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adicet Bio (LTS:0HX7) Overvalued in 2026?
Based on GuruFocus' analysis, Adicet Bio stock appears to be overvalued.
The current stock price of $8.82 is trading 1860.3% above its estimated GF Value™ of $0.45.
GuruFocus considers Adicet Bio to be Significantly Overvalued.
Key valuation signals for LTS:0HX7:
Days Payable: 247.93
GF Value™: $0.45 vs. price of $8.82 (1860.3% above fair value)
Industry Position: 123% above the Biotechnology median (#999999 of 706)
No single metric tells the full story. See the LTS:0HX7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adicet Bio Inc is a clinical-stage biotechnology company based in the United States that develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Its approach uses off-the-shelf donor-derived gamma delta T cells engineered with chimeric antigen receptors (CARs) to provide durable activity without the need for patient-specific manufacturing. The company's lead candidate, prulacabtagene leucel (prula-cel), is a CD20-targeting CAR gamma delta T cell therapy in development for autoimmune indications. Adicet is also advancing earlier-stage programs, including ADI-212, a gene-edited, armored candidate targeting prostate-specific membrane antigen (PSMA) for oncology. The company's pipeline spans both autoimmune and solid tumor applications. As a clinical-stage business, Adicet does not yet generate product revenue and funds its research and development through equity financings, partnerships, and other capital sources. Its activities are centered on preclinical and clinical development, regulatory interactions, and manufacturing scale-up.
23GF Score
Get the complete analysis for LTS:0HX7
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HX7 has been successfully added to your 
